Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2025-11-25 Report Publication Anno…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 500 characters) stating that the CEO is presenting at a conference and explicitly provides the presentation as an attachment. According to the 'Menu vs Meal' rule, an announcement stating that a report or presentation is attached is classified as a Report Publication Announcement (RPA).
2025-11-25 English
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is a 'Financial calendar' listing future dates for the release of various reports (Annual, Quarterly, Half-yearly) and the Annual General Meeting. It does not contain the actual financial data or reports themselves, but rather serves as a schedule announcement. Since it is a short notification regarding the timing of future report publications, it fits the definition of a Report Publication Announcement (RPA).
2025-11-11 English
Mandatory notification of trade - Attachment: MH_20251027_KRT1500.pdf
Director's Dealing Classification · 100% confidence The document is a KRT-1500 form, which is the standard Norwegian regulatory form for reporting transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons. The content explicitly details a share purchase by the CEO of Gentian Diagnostics ASA, including the transaction date, volume, price, and instrument details. This falls directly under the 'Director's Dealing' category.
2025-10-28 Norwegian
Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is a notification of a share purchase by a primary insider (CEO Matti Heinonen). It explicitly mentions 'Mandatory notification of trade' and 'PDMR notification' (Person Discharging Managerial Responsibilities), which corresponds to the definition of a Director's Dealing report.
2025-10-28 English
Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detection of Neonatal Infections and Sepsis - Attachment: jENScongress_press release.pdf
Regulatory Filings Classification · 100% confidence The document is a press release announcing the results of a clinical study regarding a medical diagnostic product (calprotectin assay). It does not constitute a financial report, regulatory filing, or shareholder communication. As it is a general corporate announcement regarding product research and clinical findings that does not fit into specific financial categories like earnings or governance, it falls under the general regulatory/corporate announcement category.
2025-10-23 English
Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detection of Neonatal Infections and Sepsis
Regulatory Filings Classification · 100% confidence The document is a press release announcing the results of a clinical study regarding a diagnostic test (calprotectin) developed by Gentian Diagnostics. It does not contain financial statements, regulatory filings, or corporate governance updates. As it is a general corporate announcement regarding product research and development, it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement.
2025-10-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.